drugset / Trial / NCT00123370
Trial of Modafinil for Methamphetamine Dependence
Phase 2
Unknown
87 enrolled
The University of New South Wales
Australian Government Department of Health and Ageing · collabKirketon Road Centre, Sydney Hospital · collabSt Vincent's Hospital, Sydney · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
The study aims to evaluate the safety and efficacy of modafinil (200 mg/day) over 10 weeks plus a tailored cognitive behavioural therapy program in the treatment of methamphetamine dependence.
Timeline
- Start
- 2006-07
- Primary completion
- —
- Completion
- 2007-09
Publications
- Shearer J, Shanahan M, Darke S, Rodgers C, van Beek I, McKetin R, Mattick RP. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Rev. 2010 May;29(3):235-42. doi: 10.1111/j.1465-3362.2009.00148.x.
- Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J, Brady D, McKetin R, Mattick RP, Wodak A. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009 Feb;104(2):224-33. doi: 10.1111/j.1360-0443.2008.02437.x.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Modafinil | Small molecule | 200 mg | — |